A 32-year-old man from Delhi presents with a 4-month history of productive cough, fever, and night sweats. He was diagnosed with pulmonary tuberculosis 6 months ago and completed 2 months of standard DOTS (RIPE regimen). Despite adherence, sputum smear microscopy remains positive at month 4 of treatment. Chest X-ray shows cavitary lesions in the right upper lobe. Sputum culture and drug susceptibility testing (DST) reveal resistance to both isoniazid and rifampicin. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient meets the diagnostic criteria for **multidrug-resistant tuberculosis (MDR-TB)**: resistance to both isoniazid and rifampicin, the two most potent first-line agents. The clinical failure (persistent positive sputum at month 4 despite adherence) and DST confirmation mandate a switch to MDR-TB therapy. ## MDR-TB Treatment Regimen **Key Point:** MDR-TB requires a prolonged, intensive regimen with second-line drugs. The WHO-recommended regimen (2023 update) consists of: 1. **Intensive phase (6–8 months):** Fluoroquinolone (levofloxacin or moxifloxacin) + injectable agent (amikacin or streptomycin) + bedaquiline + pyrazinamide ± ethambutol 2. **Continuation phase (12–14 months):** Fluoroquinolone + bedaquiline + pyrazinamide ± ethambutol **Total duration:** 20 months (6–8 months intensive + 12–14 months continuation) ## Why Each Option Is Evaluated | Feature | Standard DOTS | MDR Regimen | XDR Regimen | |---------|---------------|-------------|-------------| | **Drugs** | RIPE | FQ + injectable + bedaquiline | Linezolid + newer agents | | **Duration** | 6 months | 20 months | 20–24 months | | **Indication** | Drug-susceptible TB | Resistance to INH + RIF | Resistance to FQ + injectable | | **This patient** | ✗ Failed | ✓ Confirmed MDR | ✗ Not XDR yet | **High-Yield:** The presence of DST-confirmed MDR-TB (INH + RIF resistance) mandates second-line therapy. Continuing or modifying the first-line regimen will result in treatment failure and emergence of XDR-TB. **Clinical Pearl:** Bedaquiline (a mycobacterial ATP synthase inhibitor) is now a core component of MDR-TB regimens and significantly improves outcomes compared to older injectable-based regimens. ## Why XDR Regimen Is Not Yet Indicated XDR-TB is defined as MDR-TB *plus* resistance to a fluoroquinolone *and* an injectable agent. This patient has not yet been tested for resistance to second-line drugs. XDR regimens (containing linezolid, moxifloxacin, bedaquiline, and newer agents like delamanid) are reserved for confirmed XDR-TB and are associated with higher toxicity and cost.